...
首页> 外文期刊>Expert opinion on therapeutic targets >Fatty acid receptors as new therapeutic targets for diabetes.
【24h】

Fatty acid receptors as new therapeutic targets for diabetes.

机译:脂肪酸受体是糖尿病的新治疗靶标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

G-protein-coupled receptors (GPCRs) are key regulators of several physiological functions. Their roles in cellular signal transduction have made them the target for majority of all currently prescribed drugs. Additionally, there are many orphan GPCRs that provide potential novel therapeutic targets. Several GPCRs are involved in metabolic regulation and glucose homeostasis such as GLP-1 receptor, glucagon receptor, adiponectin receptor and so on. Recently, free fatty acids (FFAs) have been demonstrated as ligands for orphan GPCRs and have been proposed to play a critical role in physiological glucose homeostasis. GPR40 and GPR120 are activated by medium and long-chain FFAs, whereas GPR41 and GPR43 can be activated by short-chain FFAs. GPR40, which is preferentially expressed in pancreatic beta-cells, mediates the majority of the effects of FFAs on insulin secretion. In this review, these findings and also critical analysis of these GPCRs as novel targets for diabetes are discussed.
机译:G蛋白偶联受体(GPCR)是几种生理功能的关键调节因子。它们在细胞信号转导中的作用使它们成为目前所有处方药中大多数的靶标。另外,有许多孤儿GPCR可提供潜在的新型治疗靶标。几种GPCR参与代谢调节和葡萄糖稳态,例如GLP-1受体,胰高血糖素受体,脂联素受体等。近年来,已证明游离脂肪酸(FFA)作为孤儿GPCR的配体,并已提出在生理葡萄糖稳态中起关键作用。 GPR40和GPR120被中链和长链FFA激活,而GPR41和GPR43可以被短链FFA激活。优先在胰腺β细胞中表达的GPR40介导了FFA对胰岛素分泌的大部分作用。在这篇综述中,讨论了这些发现以及对这些GPCR作为糖尿病新靶点的严格分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号